Novogen's TRXE-009 shows potential

Novogen Ltd. (Nasdaq: NVGN) announced that TRXE-009 demonstrated potential to kill brain cancer stem cells sending the stock price soaring $1.09 to $3.61.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.